Drug intelligence / Profile preview

elasomeran + tozinameran + ChAdOx1 nCoV-19 + Ad26.COV2.S + BBIBP-CorV

Development stage: Unknown
Lead developer: Moderna
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This is a combination of five different COVID-19 vaccines: elasomeran (Moderna's mRNA vaccine), tozinameran (Pfizer/BioNTech's mRNA vaccine), ChAdOx1 nCoV-19 (Oxford/AstraZeneca's adenovirus vector vaccine), Ad26.COV2.S (Johnson & Johnson's adenovirus vector vaccine), and BBIBP-CorV (Sinopharm's inactivated virus vaccine). Each vaccine works through different mechanisms to provide immunity against SARS-CoV-2. The mRNA vaccines (elasomeran and tozinameran) deliver genetic instructions for cells to produce the viral spike protein, triggering an immune response. The adenovirus vector vaccines use modified adenoviruses to deliver genetic material coding for the spike protein. BBIBP-CorV uses an inactivated form of the SARS-CoV-2 virus.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on elasomeran + tozinameran + ChAdOx1 nCoV-19 + Ad26.COV2.S + BBIBP-CorV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elasomeran + tozinameran + ChAdOx1 nCoV-19 + Ad26.COV2.S + BBIBP-CorV.

Explore the full profile